Table 2. Genotypic characterization of the strains and derived cultures exposed to isoniazid (adaptation process A).
| Genotype MTBDRplus | DNA Sequencing | |||||
| Strain/Passage | rpoB | mabA-inhA | katG | mabA-inhA | katG | MIRU-VNTR profile |
| H37Rv | Wt | wt | wt | wt | wt | H37Rv |
| H37Rv INH (a)1 | Wt | wt | wt | wt | wt | H37Rv |
| H37Rv INH (a)2 | Wt | wt | wt | wt | wt | |
| H37Rv INH (a)3 | Wt | wt | Δ katG | wt | Δ katG | |
| H37Rv INH (a)5 | Wt | wt | Δ katG | wt | Δ katG | H37Rv |
| H37Rv INH (a)13 | Wt | wt | Δ katG | wt | Δ katG | |
| H37Rv INH (a)26 | Wt | wt | Δ katG | wt | Δ katG | H37Rv |
| 401/06 | Wt | wt | wt | wt | wt | A |
| 401/06 INH (a)5 | Wt | wt | wt | wt | wt | A |
| 401/06 INH (a)13 | Wt | wt | wt | wt | wt | |
| 401/06 INH (a)26 | Wt | wt | wt | wt | wt | A |
| 267/05 | S531L | wt | wt | wt | wt | B |
| 267/05 INH (a)5 | S531L | wt | wt | wt | wt | B |
| 267/05 INH (a)13 | S531L | wt | wt | wt | wt | |
| 267/05 INH (a)26 | S531L | wt | wt | wt | wt | B |
| 359/03 | S531L | wt | wt | wt | wt | C |
| 359/03 INH (a)1 | S531L | wt | wt | wt | wt | C |
| 359/03 INH (a)2 | S531L | wt | wt | wt | TGG438→STOP | |
| 359/03 INH (a)5 | S531L | wt | wt | wt | TGG438→STOP | C |
| 359/03 INH (a)13 | S531L | wt | wt | wt | TGG438→STOP | |
| 359/03 INH (a)26 | S531L | wt | wt | wt | TGG438→STOP | C |
Legend: INH: isoniazid; RIF: rifampicin; wt: wild type; Δ: deletion of katG gene; S: serine; L: leucine. MIRU-VNTR profile A: 2,4,2,2,3,4,2,3,2,3,2,4,2,2,6,1,6,3,1,3,1,7,2,2; profile B: 2,4,4,2,3,4,3,3,2,4,2,4,2,2,6,1,5,3,1,3,1,5,2,2; profile C: 2,1,4,2,1,3,2,3,2,2,2,5,1,2,6,1,6,3,3,3,2,4,2,2.